News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

ReACT: Long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma

Al's Comment:

 Impressive long term survival state presented at the SNO conference of Rindopepimut plus Avastin vs. Avastin alone for recurrent Glioblastoma patients. Highlight: at 2 years the Rindopeimut + Avastin group had 25% of patients alive. The Avastin alone group had 0% alive.  

This is just a simple shot in the arm which adds no significant side effects - just local reaction at the injection site like a flu shot.


Posted on: 11/21/2015

ReACT: Long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma

Click here for full article

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740